Louise Warme appointed to the Board of Capitainer
Capitainer announces the appointment of Louise Warme, Head of We Venture Capital, and Andreas Lindblom to Capitainer’s board of directors. These additions come at a pivotal moment for Capitainer as it continues to grow, reinforcing its commitment to leadership in the diagnostics industry.
Louise Warme, Head of We Venture Capital, joins the Capitainer board with over ten years of experience in venture capital and life science investments along experience from 17 board engagements. With a strong foundation as a medical doctor and researcher, she has showcased her leadership as the founding CEO of a medtech startup. Louise Warme currently serves as a director on the board of Axithra and as an observer on the boards of Deepull and Zetta Genomics. She is deeply committed to advancing clinical innovations, a dedication evidenced by her holding a Clinical Innovations Fellowship at the Karolinska Institutet & Royal Institute of Technology in Stockholm, Sweden.
Andreas Lindblom, Managing Partner at Sciety, brings to the board over 25 years of experience as an experienced entrepreneur with a focus on healthcare, finance, and technology. Andreas Lindblom co-founded the investment company Sciety, driven by his passion for promoting change and growth within these sectors. His unique educational background, with a degree in Physiotherapy from Karolinska Institutet and a Master’s degree in Applied Physics from Stockholm University, underpins his solid understanding of both healthcare and technology. His entrepreneurial spirit and dedication to the Nordic life science ecosystem underscore his commitment to making a meaningful impact in the industry.
The appointment of Louise Warme and Andreas Lindblom to Capitainer’s board marks a strategic move, enhancing the company’s ability to navigate the diagnostics market effectively. Their collective experience and insights will be instrumental in guiding Capitainer’s strategic directions and reinforcing its position as a market leader.
Capitainer AB, founded in 2016, is a Swedish MedTech company at the forefront of developing patient-centric solutions for blood, plasma, and urine self-sampling. Their innovative technology enables precise fluid collection and drying on user-friendly cards, eliminating the need for complex cold chain logistics. With market-leading precision and accuracy, their products are ideal for a wide range of sectors, including clinical biomarkers, drug monitoring, genomics, and research studies.
This content has been taken from the article published in the following link:
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.